The utility of cyclodextrins for enhancing oral bioavailability

被引:472
作者
Carrier, Rebecca L.
Miller, Lee A.
Ahmed, Mran
机构
[1] Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA
[2] Pfizer Inc, Ann Arbor, MI 48105 USA
[3] Pfizer Inc, Groton, CT 06340 USA
关键词
cyclodextrins; solubilization; bioavailability; modeling; forniulation;
D O I
10.1016/j.jconrel.2007.07.018
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cycloclextrins (CD) have been utilized extensively in pharmaceutical formulations to enhance oral bioavailability. A critical review of the literature in which cyclodextrins were utilized for this purpose was conducted. The goal of this review was to determine if quantitative guidelines for drug and cyclodextrin properties necessary for bioavailability enhancement using cyclodextrins could be extracted. Twenty-eight studies were examined in which the focus was on the use of cyclodextrins as solubilizers to enhance bioavailability. Commonly observed factors included: utilization of pre-formed complex rather than physical mixtures, drug hydrophobicity (logP > 2.5), low drug solubility (typically< 1 mg/ml), moderate binding constant (< 5000 M-1), low dose (< 100 mg), and low CD:drug ratio (< 2: 1). These general guidelines, however, did not apply to all studies. Quantitative guidelines useful to a formulation scientist considering the use of cyclodextrins were difficult to develop due to missing information and the complicated manner in which drug and cyclodextrin properties interact to influence key drug delivery processes (e.g., dissolution, absorption). The mechanisms by which cyclodextrins influence these processes, again emphasizing solubilization capabilities, are discussed to provide further insight into why cyclodextrins will increase bioavailability in certain cases but not influence or possibly decrease bioavailability in others. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:78 / 99
页数:22
相关论文
共 136 条
[111]   Evaluation of a sulfobutyl ether β-cyclodextrin as a solubilizing/stabilizing agent for several drugs [J].
Ueda, H ;
Ou, D ;
Endo, T ;
Nagase, H ;
Tomono, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1998, 24 (09) :863-867
[112]  
UEDA H, 1989, J PHARM BIOMED ACTA, V7, P642
[113]   EFFECTS OF ALPHA-CYCLODEXTRINS AND BETA-CYCLODEXTRINS ON BASE-CATALYZED ISOMERIZATION OF PROSTAGLANDIN-A1 AND PROSTAGLANDIN-A2 [J].
UEKAMA, K ;
HIRAYAMA, F ;
DAIGUJI, M .
CHEMISTRY LETTERS, 1978, (04) :327-330
[114]   ENHANCED BIOAVAILABILITY OF DIGOXIN BY GAMMA-CYCLODEXTRIN COMPLEXATION [J].
UEKAMA, K ;
FUJINAGA, T ;
OTAGIRI, M ;
SEO, H ;
TSURUOKA, M .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1981, 4 (09) :735-737
[115]   Design and evaluation of cyclodextrin-based drug formulation [J].
Uekama, K .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2004, 52 (08) :900-915
[116]  
UEKAMA K, 1987, CRIT REV THER DRUG, V3, P1
[117]   IMPROVEMENT OF DISSOLUTION AND ABSORPTION CHARACTERISTICS OF BENZODIAZEPINES BY CYCLODEXTRIN COMPLEXATION [J].
UEKAMA, K ;
NARISAWA, S ;
HIRAYAMA, F ;
OTAGIRI, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1983, 16 (03) :327-338
[118]  
UEKAMA K, 1983, J PHARMACOBIO-DYNAM, V6, P124
[119]   IMPROVEMENT OF THE ORAL BIOAVAILABILITY OF DIGITALIS GLYCOSIDES BY CYCLODEXTRIN COMPLEXATION [J].
UEKAMA, K ;
FUJINAGA, T ;
HIRAYAMA, F ;
OTAGIRI, M ;
YAMASAKI, M ;
SEO, H ;
HASHIMOTO, T ;
TSURUOKA, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (11) :1338-1341
[120]   PERACYLATED BETA-CYCLODEXTRINS AS NOVEL SUSTAINED-RELEASE CARRIERS FOR A WATER-SOLUBLE DRUG, MOLSIDOMINE [J].
UEKAMA, K ;
HORIKAWA, T ;
YAMANAKA, M ;
HIRAYAMA, F .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1994, 46 (09) :714-717